(a) The purpose of this section is to expand the harm reduction strategies available in Delaware to address the epidemic level of drug overdose deaths through the distribution of fentanyl testing strips. Fentanyl is a potent opioid that is increasingly being mixed into illicitly sold drugs, often without the buyer's knowledge. In 2018, fentanyl was involved in 72% of overdose deaths in Delaware. The distribution of fentanyl testing strips provides an opportunity to prevent potential overdose deaths.
(b) For purposes of this section, “person” means 1 of the following that provides aid to drug users without the expectation of monetary or other compensation from the individual aided:
(1) A lay individual.
(2) A nonprofit organization.
(c) This section does not apply to any of the following:
(1) A manufacturer or distributor of fentanyl testing strips.
(2) A pharmacy.
(3) A hospital.
(4) A medical clinic.
(5) A for profit organization.
(6) A credentialed individual.
(d) A person may distribute functional fentanyl testing strips to determine the presence of fentanyl or fentanyl-related substances.
(e) A person who provides functional fentanyl testing strips to an individual to determine the presence of fentanyl or fentanyl-related substances under this section must do so in good faith and with reasonable care.
(f) A person who provides functional fentanyl testing strips to an individual to determine the presence of fentanyl or fentanyl-related substances is not subject to civil damages in excess of the limits of any applicable insurance coverage, unless it is established that the person caused injuries or death wilfully, wantonly, or recklessly or by gross negligence.
(g) Nothing in this section is intended to waive the State's sovereign immunity or the privileges and immunities under Chapter 40 of Title 10.